2002, Number 2
<< Back Next >>
Enf Infec Microbiol 2002; 22 (2)
Infections produced by Gram-positive cocci. Controversies related to development of bacterial resistance
Morfín OR, Rangel FS, Rodríguez NE
Language: Spanish
References: 45
Page: 46-50
PDF size: 48.77 Kb.
ABSTRACT
Development of bacterial resistance to antibiotics is a worldwide public health problem. In the United States of America 64% of bacterial nosocomial infections are produced by Gram-positive cocci and the percentage of resistance in high. These are patogens with great ability to disseminate as well as with ability to develop resistance to most of the antibiotics currently in use. Today,
S. aureous resistant to glicopeptids is a problem that makes difficult the choice of adequate drugs against these emergent bacteria. In this situation we must select the antibiotic with better activity, pharmacokinetic and pharmacodynamic as well as the lowest risk. Among these drugs are the oxazolidinonas.
REFERENCES
Edmond MB, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44.
Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2000;14 (2): 293-319.
Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13(4):686-707.
Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13(4):686-707.
Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002;15(3):430-8.
Edmond MB, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20(5):1126-33.
Hiramatsu K, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 1997;40(1):135-6.
Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29(4 Suppl):N64-8.
Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8(8):802-7.
Sieradzki K, et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340(7):517-23.
Fridkin SK, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135(3):175-83.
Gonzalez C, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29(5):1171-7.
Burnie J, et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000;31(3):684-9.
Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7(2):178-82.
Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34(12): 1613-20.
Low DE, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46(5):1295-301.
Garrett DO, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999;20(3):167-70.
Smith TL, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340(7):493-501.
Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002;2(9):530-8.
Hussain FM, et al. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002;186(5):661-7.
Edmond MB, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23(6):1234-9.
Sieradzki K, et al. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 1999;37(1):39-44.
Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001;85(1):1-17.
Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis, 2000;30(1):146-51.
Rubinstein E, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32(3):402-12.
Stevens DL, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34(11):1481-90.
Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22(5):387-94.
Luna CM, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111(3):676-85.
Rello J, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(1):196-200.
Trouillet JL, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157(2):531-9.
Ibrahim EH, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118(1):146-55.
Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(Suppl 4):S131-8.
Iregui M, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122(1):262-8.
Leibovici L, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244(5):379-86.
Ena J, et al. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. Jama 1993;269(5): 598-602.
Fridkin SK, et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 1999;28(5):1119-25.
Daschner FD, et al. Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery. J Antimicrob Chemother 1987;19(3):359-62.
Lamer C, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37(2):281-6.
Martin C, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994;38(2):396-9.
Cruciani M, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38(5):865-9.
Lundstrom TS, Sobel JD. Antibiotics for Gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid. Infect Dis Clin North Am 2000;14(2):463-74.
Ford CW, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996;40(6): 1508-13.
Shinabarger DL, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41(10):2132-6.
Swaney SM, et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42(12):3251-5.
Plouffe JF. Emerging therapies for serious Gram-positive bacterial infections: a focus on linezolid. Clin Infect Dis 2000;31 (Suppl 4):S144-9
Full text